25.03.2025 14:06 Rita Longobardi
Ten startups have been selected for the 2025 Venture Leaders Biotech program, which will take them to Boston from June 23rd to 27th as part of the Swiss National Startup Team. During their roadshow, the entrepreneurs will connect with international investors and industry leaders, acquiring expertise to help scale their ventures. Venture Leaders Biotech is organized by Venturelab in partnership with Swissnex Boston & New York and supported by the University of Basel, EPFL, ETH Zurich, Hansjörg Wyss, Kellerhals Carrard, and VISCHER.
After reviewing over 70 applications, the jury of investors and biotech experts selected the ten startups to participate in the Boston roadshow, a key program in one of the world’s leading life science hubs. The program will allow the selected entrepreneurs to meet potential investors and industry experts, accelerating their expansion into the US market.
The 2025 selection spans a wide array of innovative scientific fields such as advanced drug discovery for degenerative and aging-related diseases to revolutionary stem-cell-based blood platelet products, innovative cell therapies or next-generation biomaterials for controlled drug delivery. The Venture Leaders Biotech, which collectively showcases the dynamic potential and diversity of Switzerland’s biotech ecosystem, kick-off the program pitching at the Swiss Biotech Day in Basel on May 5, 2025.
"Getting ready for this roadshow for the 20th year is a great reflection of the quality of innovation of the new startups involved," said Jordi Montserrat, Managing Partner of Venturelab. "I’m looking forward to being part of this new edition and assisting the team with their fundraising and international expansion."
The 10 startups will follow in the footsteps of high-flying former team members such as Araris Biotech (recently announced its acquisition for USD 1.1 billion), Covagen (acquired by Johnson & Johnson), Versantis (acquired by Genfit), AMAL Therapeutics (acquired by Boehringer Ingelheim), NBE-Therapeutics (acquired by Boehringer Ingelheim), Alentis (USD 105 million funding round in 2023), and BioVersys (recent IPO on the SIX Swiss Exchange).
"What an amazing road trip we have made," said Maria van Dongen, Co-Founder of Allegria Therapeutics and Venture Leaders Biotech 2024—who closed a USD 3.5 million Seed Round last year. "Connecting with so many knowledgeable players in the Boston Biotech ecosystem was mind-blowing. I am confident that this trip will be paying off as ALLEGRIA Therapeutics is developing."
Venture Leaders Biotech is organized by Venturelab in partnership with Swissnex in Boston & New York and supported by the University of Basel, EPFL, ETH Zurich, Hansjörg Wyss, Kellerhals Carrard, and VISCHER.
Follow the entrepreneurs and the Venture Leaders Biotech roadshow on social media using the hashtag #VLeadersBiotech or on https://www.venturelab.swiss/venture-leaders-biotech.
About Venture Leaders
The Venture Leaders – the members of the Swiss National Startup Team – have a clear goal: envisioning themselves as global players, they want to take the first step towards their global expansion. Venturelab has over 20 years of experience bringing Switzerland’s best entrepreneurs to the heart of the global technology hubs: Silicon Valley, Boston, China, London, Barcelona, and Munich. Companies founded by the 582 Venture Leaders alumni have created more than 12,900 jobs and raised more than CHF 8,9 billion in investment capital. For more information, visit www.venture-leaders.ch, and discover all the alumni here.
Meet the Venture Leaders Biotech 2025:
Founded in 2004 as a spin-off from the University of Zurich, Molecular Partners, a Roadshow Partner of Venture Leaders Biotech, has spent two decades developing...
Read more
Twenty years after co-founding Molecular Partners (MP), Patrick Amstutz and Michael Stumpp reflect on building a company around a novel drug class—DARPin therap...
Read more
In late June, the Venture Leaders Biotech 2025 team set out for Boston with a focused mission: to connect with leading investors and experts in one of the world...
Read more
Boston is a global hub for biotech, offering access to leading research, investors, and industry networks. As part of the 2025 Venture Leaders Biotech roadshow,...
Read more
